Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Reproxalap - Aldeyra Therapeutics

Drug Profile

Reproxalap - Aldeyra Therapeutics

Alternative Names: ADX 102; NS 2; NS-2-Aldeyra

Latest Information Update: 09 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aldeyra Therapeutics
  • Class Anti-inflammatories; Eye disorder therapies; Quinolines; Skin disorder therapies; Small molecules
  • Mechanism of Action Malondialdehyde inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sjogren-Larsson syndrome
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Allergic conjunctivitis; Dry eyes; Sjogren-Larsson syndrome; Uveitis
  • Preclinical Inborn error metabolic disorders; Inflammation
  • No development reported Contact dermatitis; Mucositis

Most Recent Events

  • 01 Nov 2019 Efficacy and adverse events data from a phase I/II trial for Allergic Conjunctivitis released by Aldeyra Therapeutics
  • 31 Oct 2019 Aldeyra Therapeutics plans the phase III INVIGORATE trial for Allergic Conjunctivitis(Ophthalmic) in first half of 2020
  • 08 Aug 2019 Aldeyra Therapeutics plans to meet the US FDA to confirm the design of a second phase III trial for Allergic conjunctivitis in the fourth quarter of 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top